Key Highlights

  • Alzai Health (TSXV:ALZI) fell 5.00% to a quoted CAD 0.19, with a 14-period RSI of 23.48.
  • Alzai Health sells a non-invasive, AI-driven tool that analyzes existing patient records to screen for Alzheimer’s disease and related dementias.
  • The company completed its initial public offering in June 2026, signed a Marketing services agreement on August 12 and announced a marketing arrangement with Centauri Health Solutions.
  • No company-specific catalyst was identified in the disclosures reviewed. The quote is below the IPO unit price, and commercial traction and further financing are the main items to monitor.

Introduction

Alzai Health Corp. (TSXV:ALZI) is a Toronto-based health technology company listed on the TSX Venture Exchange that offers an AI-driven screening tool for Alzheimer’s disease risk. Its shares fell 5.00% to CAD 0.19 on November 3, 2026, with a 14-period RSI of 23.48. The company listed only in 2026 and no market Capitalization figure was supplied, so the question for investors is how a decline of 5.00% relates to a newly listed company’s early trading.

Catalyst and Latest Updates

Alzai Health’s product is an AI-driven, non-invasive risk screening tool for Alzheimer’s disease and related dementias. It analyzes data already in routine clinical records, aiming to identify cognitive decline earlier, when most patients are not yet diagnosed.

The company filed its final prospectus for an initial public offering of units, each combining a share and a half-warrant, on April 21, 2026, with Haywood Securities as agent, and the offering was completed in June before the shares began trading on the TSX Venture Exchange. Proceeds were earmarked for research and development, sales and marketing and working capital. On August 12, 2026, it signed a market awareness and Digital Marketing services agreement with Euro Digital Media Ltd., subject to exchange approval and with no securities issued as payment. It also announced a strategic marketing agreement with Centauri Health Solutions to expand AI-assisted Alzheimer’s risk identification in the United States.

No company-specific catalyst was identified in the disclosures reviewed. The disclosures reviewed identify no announcement on November 3.

Volume, Data and Context

A price of CAD 0.19 is well below the IPO unit price stated in the company’s prospectus, a comparison taken from that document and not from the data provided. A decline of 5.00% on a low-priced stock may reflect only a small change in price, as small increments are large percentages.

No market capitalization figure was supplied for this report, so none is stated. Investors can check the share count in the company’s filings.

The 14-period RSI of 23.48 indicates strongly negative recent momentum. RSI, or Relative Strength Index, compares the size of recent gains with the size of recent losses, and readings at the low end of its scale are conventionally described as oversold. The timeframe of the indicator was not specified. A low reading describes how the price has behaved; it does not explain the weakness, and it does not signal that a Reversal is coming. The session’s decline of 5.00% is consistent with that momentum but does not establish its cause.

Taken together, the data describe a recently listed health technology company whose shares are quoted below the offering price and show very weak momentum, with no confirmed company-specific cause.

Risks and What to Watch

Commercial risk is central. A screening tool needs health system and payer adoption, and the company must show clinical value to customers.

Regulatory and privacy risk apply to software that analyzes patient records, including health data rules in each Jurisdiction where it operates.

Funding risk follows, since an early-stage company with small IPO proceeds will likely need more capital.

Promotional activity can drive short-term trading. The company’s marketing agreements are reasons to read announcements closely, and a quote below the IPO price means recent investors hold losses.

Investors should watch for customer contracts and the Centauri Health Solutions rollout, exchange approval of the marketing agreement, quarterly results, further financing and regulatory developments.

Outlook

The company intends to expand sales and marketing of its screening tool, particularly in the United States. This is a company objective rather than a guarantee, and the price and RSI do not measure progress.

Where Things Stand

Alzai Health (TSXV:ALZI) fell 5.00% to a quoted CAD 0.19, with an RSI of 23.48. What is known is that momentum has been strongly negative, that the shares fell 5.00% on the session and that the company completed its IPO in June. What remains uncertain is what caused the decline and how the company is valued, since no market capitalization was supplied and no catalyst was identified. Customer announcements and quarterly results would give the clearest evidence. The figures should be treated as a snapshot, since the time of the data was not provided.